Alzheimer's and Leqembi: What we Know So Far
Inception Point AI
Alzheimer's disease is a progressive neurodegenerative disease that is the most common cause of dementia. It is characterized by the loss of neurons and synapses in the brain, which leads to a decline in cognitive function and memory. Leqembi (lecanemab) is a monoclonal antibody that has been shown to slow the progression of Alzheimer's disease in clinical trials. It was approved by the FDA on June 6, 2023, for the treatment of people with mild cognitive impairment or early Alzheimer's disease. Leqembi works by binding to beta-amyloid, a protein that forms plaques in the brains of people with Alzheimer's disease. These plaques...
Download ScreenshotsAbout PodLP
PodLP is the leading podcast app for feature phones. With 10M+ installs in nearly every country, PodLP is available for KaiOS on the KaiStore and JioStore, as well as Cloud Phone and Android. If you're interested in promoting "Alzheimer's and Leqembi: What we Know So Far" on PodLP, contact sales@podlp.com.
Screenshots are mockup renders of PodLP for KaiOS. Actual design may vary based on platform, operating system, and app version.
